Kim Helen Susan
SEC Form 4 insider trading activity
Kim Helen Susan has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jan 12, 2026.
On the most recent filing, Kim Helen Susan is listed as Director, 10% Owner at Aktis Oncology, Inc. Inside the rolling window, Kim Helen Susan reported 1 open-market purchase totaling $15.0M in AKTS and no open-market sales.
Companies traded
Other insiders at AKTS
Insider Buying
$15.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kim Helen Susan made?
Kim Helen Susan has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does Kim Helen Susan trade?
Kim Helen Susan has filed SEC Form 4 disclosures for 1 company, including AKTS.
When was Kim Helen Susan's most recent SEC Form 4 filing?
Kim Helen Susan's most recent SEC Form 4 filing on Tracefour is dated Jan 12, 2026.
What is Kim Helen Susan's total buy and sell value in the current window?
Inside the rolling retention window, Kim Helen Susan bought $15.0M and sold $0 based on SEC Form 4 filings.
What was Kim Helen Susan's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 835,000 AKTS shares on 2026-01-12, worth $15.0M, per SEC Form 4 filings.